Drugs / GR1801
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05846568 | Oct 2022 → Sep 2023 | rabies | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GR1801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05846568 ↗ |
| Modality | Monoclonal antibody | “GR1801 injections are a bispecific monoclonal antibody that exhibit a wide spectrum of activity against various wild-type rabies strains in vitro.” NCT05846568 ↗ |
| Route | Intramuscular | “GR1801 injections are administered by wound infiltration injection or by intramuscular injection.” NCT05846568 ↗ |
| Route | Other | “GR1801 injections are administered by wound infiltration injection or by intramuscular injection.” NCT05846568 ↗ |